Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC

• Status: Completed
• Trial end date: 2021-06-06
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-arm non-interventional study (NIS) to evaluate the effectiveness, safety and quality of life (QoL) in patients with advanced NSCLC receiving the combination of nab-paclitaxel and carboplatin as first line palliative therapy in a real life setting.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: iOMEDICO AG
• Collaborators: Bristol-Myers Squibb; Celgene Corporation
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Histologically confirmed diagnosis of locally advanced / metastatic, unresectable NSCLC

• According to SmPC

Exclusion Criteria:

• According to SmPC